Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers want to find the best dose of ELA026 to use in people with secondary hemophagocytic lymphohistiocytosis (sHLH). When you have sHLH, certain white blood cells become overactive and attack other healthy blood cells. The white blood cells damage your own healthy tissues and organs. sHLH is usually triggered by another disease, such as cancer, infection, or autoimmune disease.
Researchers want to find the best dose of BMS-986458 to use alone and with rituximab to treat lymphoma. The people in this study have non-Hodgkin lymphoma (NHL) that came back or keeps growing after treatment.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of NT-175 in people with advanced solid tumors. The people in this study have cancers that are inoperable (cannot be surgically removed) or metastatic (have spread). The types of tumors include:
People with endometrial cancer often gain weight during and after chemotherapy. Medicines to reduce the risk of an allergic reaction for people receiving chemotherapy can also raise blood sugar. Weight gain can affect overall health and cancer recovery.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing ado-trastuzumab emtansine (T-DM1) to treat salivary gland cancer. The people in this study have cancer that is operable (can be removed with surgery) and makes a protein called HER2. T-DM1 targets cancer cells that make HER2. In this study, it will be combined with radiation therapy and chemotherapy after the tumor has been removed by surgery.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Anaplastic large cell lymphoma (ALCL) is a type of T-cell cancer. This cancer has a fusion (change) in the ALK gene. The fusion gene makes a protein that promotes cancer growth and survival. This type of cancer is called ALK-positive ALCL.
Researchers in this study are assessing the combination of enfortumab vedotin with pembrolizumab immunotherapy in people with bladder cancer that has spread to nearby lymph nodes and will be surgically removed. Both medications are already used to treat bladder cancer, but their use together before surgery is considered investigational. Both drugs help the immune system attack and kill cancer cells. The study investigators will see if this combination treatment can get rid of cancer in the lymph nodes and shrink patients' tumors before surgery.
